Loading...
•
Dec 31, 2024
LabCorp Q4 2024 Earnings Report
Labcorp delivered exceptional results driven by both organic and inorganic growth.
Key Takeaways
Labcorp announced its Q4 2024 and full year results, demonstrating strong performance. Q4 revenue reached $3.33 billion compared to $3.03 billion in the previous year. The company's diluted EPS for Q4 was $1.70, a significant increase from $(1.95) in the prior year. Adjusted EPS for Q4 was $3.45 compared to $3.30 last year. Free cash flow for Q4 was $665.1 million, up from $412.4 million year-over-year. For full year 2024, revenue was $13.01 billion versus $12.16 billion in 2023, diluted EPS was $8.84 versus $4.33, adjusted EPS was $14.57 versus $13.56, and free cash flow was $1.10 billion versus $748.7 million.
Q4 revenue increased to $3.33 billion from $3.03 billion year-over-year.
Q4 diluted EPS was $1.70, a significant improvement from $(1.95) in the previous year.
Q4 adjusted EPS rose to $3.45 from $3.30 year-over-year.
Full year 2025 guidance projects revenue between $13.88 billion and $14.05 billion and adjusted EPS between $15.60 and $16.40.
LabCorp
LabCorp
LabCorp Revenue by Segment
Revenue by Segment
Diagnostics Revenue
CapyFin.comBiopharma Lab Services Revenue
CapyFin.com Forward Guidance
Labcorp provided its full-year 2025 guidance, anticipating revenue between $13.88 billion and $14.05 billion, and adjusted EPS between $15.60 and $16.40. Free cash flow is projected to be between $1.10 billion and $1.25 billion.
Positive Outlook
- Revenue of $13.88 billion to $14.05 billion; midpoint growth of 7.4%
- Adjusted EPS of $15.60 to $16.40; midpoint growth of 9.8%
- Free Cash Flow of $1.10 billion to $1.25 billion; midpoint growth of 7.2%
- Diagnostics Laboratories revenue growth of 6.5% to 7.7%
- Biopharma Laboratory Services revenue growth of 3.0% to 5.0%
Challenges Ahead
- Guidance assumes foreign exchange rates effective as of December 31, 2024.
- Enterprise level guidance includes the estimated impact from currently anticipated capital allocation, including acquisitions, share repurchases and dividends.
- 2025 Guidance includes an impact from foreign currency translation of (0.5%).
- 2025 Guidance includes an impact from foreign currency translation of (0.2%) for Diagnostics Laboratories.
- 2025 Guidance includes an impact from foreign currency translation of (1.4%) for Biopharma Laboratory Services.
Revenue & Expenses
Visualization of income flow from segment revenue to net income